|
|
||||||||
Articles |
a Author for correspondence. Fax 410-316-3690;
| Abstract |
|---|
|
|
|---|
Methods: We developed a DNA probe system, the BDProbeTecTMET, based on simultaneous strand displacement amplification and real-time fluorescence detection. The system uses sealed microwells to minimize the release of amplicons to the environment. To avoid the need for specially trained labor, the system uses a simple workflow with predispensed reagent devices; a programmable, expandable-spacing pipettor; and the 96-microwell format. Amplification and detection time was 1 h, with potential throughput up to 564 patient results per shift. We tested 122 total patient specimens obtained from a family practice clinic with the BD ProbeTecET and the Abbott LCx® amplified system for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae.
Results: Based on reportable results, the BDProbeTecET results for both organisms were 100% sensitive and 100% specific relative to the LCx.
Conclusions: The BDProbeTecET is an easy-to-use, high-throughput, closed amplification system for the detection of nucleic acid from C. trachomatis and N. gonorrhoeae and other organisms.© 1999 American Association for Clinical Chemistry
| Introduction |
|---|
|
|
|---|
For amplified DNA probe technology to become more routine and to be adopted into clinical laboratory settings having fewer skilled technologists, there is a need for simpler, higher throughput and more user-friendly systems. Recently, methods using real-time detection of amplified nucleic acids have been described(5)(10)(11). These methods represent the future in molecular diagnostics and may soon allow laboratories to attain these goals. However, none of these methods has been adapted into commercially available user-friendly systems for diagnostic settings.
We describe the first of these second-generation systems, the BDProbeTecET. This system is based on the simultaneous amplification of nucleic acids by SDA and real-time detection using fluorescence energy transfer (ET). When the BDProbeTecET system is applied to the detection of Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC), as few as 1015 GC cells or CT elementary bodies (EBs) can be detected reliably in 1 h on the instrument. The system configuration and workflow permits a throughput of up to 564 patient results per shift.
| Materials and Methods |
|---|
|
|
|---|
target regions, primers, and probes
SDA has been previously described (1)(2)(3)(4)(5), and its
principle is summarized in Figs. 1
and 2
, which are discussed further
under Results. Detection utilizes fluorescence ET as
described in Fig. 3A
and as discussed with the data under
Results. For the amplification and detection of CT,
the multicopy cryptic plasmid (12) was chosen as a target
region. The region being amplified spans the following sequence:
5'-CAGCAAATAATCCTTGGGACAAAATCAACACCTGTCGCAGCCAAAATGACAGCTTCTGATGGAATATCTTTAACAGTCTCCAATAATTCATCAACCAATG-3'.
The SDA amplification primer and bumper primer pairs (target-binding
region underlined, BsoBI restriction site bold and
italicized) are as follows: 5'-ACC GCA TCG AAT GCA TGT CTC
GGG GAG ACT GTTAAA GAT A-3' and 5'-CAT TGG TTG
ATG AAT TAT T-3'; 5'-CGA TTC CGCTCC AGA CTT CTC GGG
ACA AAA TCA ACA CCT G-3' and 5'-CAG CAA ATA ATC CTT
GG-3'. The detector probe utilized for real-time detection is
5'-(Fam)-TAG CAC CCG AG TGCT (Rox)-CGC AGC CAA AAT GAC
AGC TTC TGA TGG AA-3'.
|
|
|
For the amplification and detection of GC, a region within the multicopy pilin gene-inverting protein homologue (13) was chosen. The target region spans the following sequence: 5'-CGCAAATCATCAAAGCCATGAATGAACAGCTTGAAGTTTTAAAGGAGAAGATAAAAGAGCAGACGGAGAAGCCTAACTGCAAGGAAGGCGTGAAGCGTCTTGA-3'. The SDA amplification primer and bumper primer pairs (target-binding region underlined, BsoBI restriction site bold and italicized) are as follows: 5'-CGA TTC CGC TCC AGA CTT CTC GGG AAC AGC TTG AAG TTT T-3' and 5'-CGC AAA TCA TCA AAG-3'; 5'-ACC GCA TCG AAT GCA TGT CTC GGG TCC TTG CAG TTA GGC-3' and 5'-TCA AGA CGC TTC ACG-3'. The detector probe utilized for real-time detection is 5'-(Fam)-TAG CAC CCG AGT GCT (Rox)-TTC TCC GTC TGC TCT TTT ATC TTC TC-3'.
system hardware components
The standard system hardware components (Fig. 4
, discussed further
below) include a programmable, expandable-spacing pipettor, a
priming and warming heater, and the BDProbeTecET fluorescent reader.
For the detection of CT and GC, an additional lysing heater and lysing
rack is included for specimen processing.
|
The expandable spacing pipettor is capable of transferring samples from eight specimen tubes into microwells in a standard 8 x 12 array. The pipettor is programmable and is capable of dispensing and mixing volumes up to 1200 µL. Aerosol-resistant tips (Matrix Technologies) were used for all transfers.
The lysing rack and lysing heater are used to heat lyse specimens for CT or CT/GC testing. The lysing rack holds 96 specimen tubes and can be placed directly into the lysing heater. After the lysing step, the rack is removed to allow the samples to cool. One ergonomic feature of the rack is that it permits caps on the tubes to be removed with one hand.
The priming and warming heater contains two fixed-temperature stations capable of maintaining two distinct temperatures. Each station holds one metal microwell tray. One station, maintained at a setpoint of 72.5 °C, is used in the priming step. The second station, maintained at a setpoint of 54 °C, is used to prewarm the amplification mixture before the tray is placed into the instrument. Guide pins on this block aid in the orientation of an adhesive sealer card, which is placed onto the prewarmed microwell tray before transfer of the tray into the BDProbeTecET instrument.
The BDProbeTecET instrument is a fluorescent reader capable of maintaining constant temperature (52.5 °C), monitoring real-time fluorescence, and reporting results through an algorithm. It consists of a heated stage capable of holding one 96-microwell tray at a time. Microwell trays are scanned once per minute, using fluorescent excitation and detection through the bottom of the well. Trays are moved in one dimension on fixed rails over the optical station. The optical station consists of an optical bundle with eight branches, which permits an electronically multiplexed interrogation of eight microwells, thus eliminating the need for two-dimensional motion of the tray. Emitted light passes through a custom optical bandpass filter, is detected by a photomultiplier tube, and is analyzed by software.
urine sample collection, transport, and processing (fig.
5)
Urine specimens are collected in sterile, plastic,
preservative-free specimen collection cups. A urine processing
pouch (Becton Dickinson Microbiology Systems) is added to the
sample cup, and the sample cup is capped. The urine processing pouch
contains a proprietary material capable of removing amplification
inhibitors and stabilizing urine specimens containing CT stored up to 6
days or GC up to 4 days at 1830 °C, or 6 days at 28 °C for
specimens containing CT or GC (manuscript in preparation). At the
testing site, 4 mL of urine is removed and transferred into a 4-mL
tube. After centrifugation at 2000g for 30 min, the
supernatant is decanted. Sample diluent (2 mL) is added, the capped
sample is vortex-mixed and placed into the lysing rack. The rack is
placed into the lysing heater (114 °C) for 30 min. Samples are then
removed from the heater and cooled for 15 min at room temperature
before use.
swab sample collection, transport, and processing (fig. 5)
Male urethral specimens are collected using rayon swabs (MiniTip
CULTURETTETM DIRECT; Becton Dickinson). For the
collection of female endocervical specimens, a cleaning swab is used
first to remove mucus. The endocervical specimen is then collected with
a polyurethane-tipped swab (CULTURETTE DIRECT; Becton Dickinson). Both
male and female swab specimen types can be transported without
preservative or liquid additive to the testing laboratory at
230 °C for up to 6 days. At the testing laboratory, the swabs are
expressed into tubes supplied prefilled with 2 mL of sample diluent.
The swabs are discarded, and the expressed sample fluid is heat-lysed
and cooled as described above for urine specimens.
assay procedure
For each tray of specimens assayed, one positive control and one
negative control are included in the microwell tray set up and are
tested like samples. Their positions are determined by the user and
appear on the plate layout report generated by the instrument during
the login of specimens. A separate microwell for each control and
specimen is used for an amplification control (AC). The AC well
contains an amplifiable DNA sequence and actsto flag inhibitory
specimens. Thus, for a CT test, a 96-well plate will contain by one
positive control (which also acts as a control for CT and GC primers
and reagents), one negative control, and up to 46 samples. Each of the
48 CT wells has a corresponding AC well. For specimens being tested for
both CT and GC, one plate contains one positive control, one negative
run control, and up to 30 samples. Each of the 30 samples and two
controls requires three microwellsone for CT, one for GC, and one for
AC. Once the layout of the microwells is determined, the test is begun.
Priming microwells are placed into their respective microwell trays. Samples are lysed and then cooled at room temperature. For a CT/GC test, 600 µL of lysed and cooled specimen is aspirated from eight specimen tubes simultaneously. The pipettor tip spacing plunger is adjusted to collapse the spacing of the tips, and 150 µL is dispensed into each of three CT, GC, and AC priming wells. The remaining liquid and tips are discarded. This step continues until all specimens are dispensed into the priming tray.
The priming tray is covered and incubated at room temperature for at least 20 min, but for convenience in performing multiple runs throughout a shift, trays may incubate at room temperature for up to 6 h.
After incubation, the cover is removed from the priming microwell tray. The amplification microwells are placed in the amplification tray. The priming and amplification trays are placed into their stations on the priming and warming heater for 10 min. At the end of 10 min, 100 µL is transferred from each microwell column in the priming tray into the corresponding amplification microwell column in the warming station. The pipettor is programmed to dispense 100 µL and mix 50 µL of volume in the amplification wells three times to hydrate and mix the sample and reagents. Tips are discarded, and the same steps repeated until all samples and controls have been transferred.
After the samples are transferred, a rigid self-adhering amplification sealer is applied to permanently seal the microwells in the warming station. Paper backing is removed from the adhesive side of the sealer and the sealer is applied smoothly to the top of the microwells. Guide pins on the warming station of the priming and warming heater facilitate the alignment of the sealer onto the microwell tray.
The sealed amplification tray is placed into the BDProbeTecET instrument. Amplification, fluorescence detection, and data analysis occur in the instrument. Results are printed after the 1-h amplification and detection are complete. After the completion of the assay, the sealed microwells are lifted from the trays and discarded into a sealable plastic pouch, which provides a second layer of containment. The metal tray is rinsed with water and dried before reuse.
real-time detection kinetic plots
Various concentrations of CT (serovar LGVII, ATCC VR 902B) EBs or
GC cells (ATCC 19424) were added into sample diluent and tested
according to the assay procedure described above. Strains were obtained
from American Type Culture Collection.
clinical studies
Swab and/or urine specimens were collected from consenting
symptomatic and asymptomatic patients at a community family practice
clinic. For endocervical and penile urethral specimens, two swabs were
collected, one for testing with the Abbott LCx®
and one for testing with the BDProbeTecET.
Urine specimens were divided and assayed on both the Abbott LCx and the BDProbeTecET. The results shown are the initial test results without discrepant resolution.
| Results |
|---|
|
|
|---|
Present in the SDA reaction is a single-stranded DNA probe containing fluorescein and rhodamine labels (see Materials and Methods). The region between these labels includes a stem-loop structure. The loop comprises a recognition sequence for the BsoBI enzyme. This probe also contains a target-specific sequence 3' to the rhodamine label. Before specific target amplification by SDA, the fluorescein and rhodamine labels are proximal to each other such that any excitation of the fluorescein leads to transfer of the emitted energy to the rhodamine label. The net effect is that very little emission from excited fluorescein is detected. After SDA, the probe is converted to a double-stranded species, which is cleaved by the BsoBI restriction enzyme. This cleavage causes the physical separation of the fluorescein and rhodamine labels such that no ET from the excited fluorescein to rhodamine can occur. The net effect is that emission is detected from an excited fluorescein label, and this emission is indicative of specific amplification attributable to the presence of the target sequence.
The specific steps for the conversion of this fluorescent
single-stranded probe are shown in Fig. 2
. In step 1, a displaced strand (thick line), the probe
containing fluorescein (
) and rhodamine (), and an amplification
primer hybridize. The simultaneous extension by the DNA polymerase of
both the amplification primer and probe leads to displacement of an
extended probe (2). In step 3, the extended probe binds the
opposite strand primer and is extended (4). This extension
creates a double-stranded BsoBI site, which is flanked by
both the fluorescein and rhodamine labels. This extension step creates
a BsoBI site that lacks thioated dCTP incorporation at the
nucleotide position of BsoBI cleavage. As a consequence,
binding of BsoBI at the site causes double-stranded cleavage
instead of nicking (5); the two labels thus are physically
separated, and emission of fluorescein is detected. These steps occur
simultaneously during the SDA process. This detection process is
distinguished from Taqman in several ways, including the fact that
Taqman uses PCR, thus exploiting the 5'-3' exonuclease activity of the
Taq polymerase, whereas SDA uses exonuclease-free polymerase, and
that the Taqman method requires thermocycling for the formation of
fluorescent product.
An overview of the fluorescence ET detection process that occurs during
SDA is presented in Fig. 3
A. As seen in the kinetic plots of Fig. 3B
, the formation of
these fluorescent products is both continuous and rapid. For both CT
and GC, the detection of small numbers of cells or EBs occurs within
1 h. The doseresponse seen in Fig. 3B
allows for the potential
application of target quantification on this system.
The components of the system instrumentation and the workflow are shown
in Figs. 4
and
5. The workflow is designed to allow for multiple analytical
runs within a single shift and optimal time to first results.
For example, 96 specimens and controls can be lysed at one time. This
provides sufficient specimens for two cycles of CT assays, or three
cycles of CT/GC assays. Lysed specimens may cool from 15 min to
6 h. Once specimens are dispensed into the priming microwells,
they may be incubated up to 6 h. Thus, specimens sufficient for
additional analyses may be lysed, primed, and staged for the priming
and warming, and detection steps. With six analytical runs
achievable in a single shift, up to 180 CT/GC combination tests or up
to 276 CT assays can be performed. This AC feature can be deselected by
the user, if desired, thus allowing 94 wells for CT detection per
analytical run. For other analytes under development, the
instrument is capable of monitoring two amplification reactions in
one well, allowing for multiplex test results, such as an analyte and
internal control. In both of these cases, a throughput of up to 564
patient results can be achieved per shift.
The detection of CT and GC from clinical samples is shown in Tables
1 and
2. The algorithm resident
in the instrument reports results as positive, negative, indeterminate
(inhibited AC), or equivocal on the basis of preselected cutoff values
established using clinical specimens. The reportable results shown in
Tables 1
and 2
do not include indeterminate (two urine specimens
each in the CT assay) or equivocal specimens (two swabs in the CT assay
and one in the GC assay), which must be retested. The Abbott LCx does
not have an AC, and thus cannot report indeterminate results. Because
indeterminate and equivocal results are not reportable results, they
are not included into calculations on sensitivity or specificity. The
sensitivity and specificity for reportable results using the
BDProbeTecET CT and GC assays relative to the Abbott LCx are 100%.
|
|
| Discusssion |
|---|
|
|
|---|
Contamination with amplicons or target DNA is also minimized with the system design. The controlled dispense and aspirate programs on the pipettor prevent splattering in the transfer steps. Aerosol-resistant tips prevent sample-to-sample carryover. Because no amplification occurs in the priming wells, no amplicon contamination is possible at this stage. The sealed microwells and subsequent disposal into sealed plastic pouches provides two levels of containment from amplicon release. Thus overall, the system approach has been to "design out" cross-over and contamination potential. Internal studies on cross-contamination, where high-positive and low-positive tubes are interspersed, demonstrate 0.1% (1 of 960) cross-contamination and validate that this design out approach has met with success.
In conclusion, the BDProbeTecET system, which is based on real-time fluorescent detection and SDA, provides a new technology for the clinical setting. The system has superior throughput and time to first results, simple workflow, and minimal risk for release of amplicon contamination.
|
| Acknowledgments |
|---|
| Footnotes |
|---|
1 Nonstandard abbreviations: SDA, strand displacement amplification; ET, energy transfer; CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae; EB, elementary body; and AC, amplification control. ![]()
| References |
|---|
|
|
|---|
The following articles in journals at HighWire Press have cited this article:
![]() |
C. Piersimoni, G. Gherardi, D. Nista, and S. Bornigia Impact of a Chemistry-Based DNA Extraction Method on Performance of a Commercial Amplification Assay for Detection of Mycobacterium tuberculosis Complex J. Clin. Microbiol., January 1, 2009; 47(1): 282 - 283. [Full Text] [PDF] |
||||
![]() |
D. M. Whiley, J. W. Tapsall, and T. P. Sloots Nucleic Acid Amplification Testing for Neisseria gonorrhoeae: An Ongoing Challenge J. Mol. Diagn., February 1, 2006; 8(1): 3 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Newman, M. B. Nelson, H. B. Friedman, and C. A. Gaydos Should Female Federal Inmates Be Screened for Chlamydial and Gonococcal Infection? Journal of Correctional Health Care, April 1, 2005; 11(2): 137 - 155. [Abstract] [PDF] |
||||
![]() |
A. W. Solomon, R. W. Peeling, A. Foster, and D. C. W. Mabey Diagnosis and Assessment of Trachoma Clin. Microbiol. Rev., October 1, 2004; 17(4): 982 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. X. Wang, L. H. Sng, and L. Tay Preliminary study on rapid identification of Mycobacterium tuberculosis complex isolates by the BD ProbeTec ET system J. Med. Microbiol., January 1, 2004; 53(1): 57 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-S. Wang, K. Thornton, A. M. Kuhn, J. G. Nadeau, and T. J. Hellyer Homogeneous Real-Time Detection of Single-Nucleotide Polymorphisms by Strand Displacement Amplification on the BD ProbeTec ET System Clin. Chem., October 1, 2003; 49(10): 1599 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Cosentino, D. V. Landers, and S. L. Hillier Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by Strand Displacement Amplification and Relevance of the Amplification Control for Use with Vaginal Swab Specimens J. Clin. Microbiol., August 1, 2003; 41(8): 3592 - 3596. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Culler, A. M. Caliendo, and F. S. Nolte Reproducibility of Positive Test Results in the BDProbeTec ET System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae J. Clin. Microbiol., August 1, 2003; 41(8): 3911 - 3914. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Iwamoto, T. Sonobe, and K. Hayashi Loop-Mediated Isothermal Amplification for Direct Detection of Mycobacterium tuberculosis Complex, M. avium, and M. intracellulare in Sputum Samples J. Clin. Microbiol., June 1, 2003; 41(6): 2616 - 2622. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Piersimoni, C. Scarparo, P. Piccoli, A. Rigon, G. Ruggiero, D. Nista, and S. Bornigia Performance Assessment of Two Commercial Amplification Assays for Direct Detection of Mycobacterium tuberculosis Complex from Respiratory and Extrapulmonary Specimens J. Clin. Microbiol., November 1, 2002; 40(11): 4138 - 4142. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. BARRETT, J. G. MAGEE, and R. FREEMAN An evaluation of the BD ProbeTec ET system for the direct detection of Mycobacterium tuberculosis in respiratory samples J. Med. Microbiol., October 1, 2002; 51(10): 895 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Foy and H. C. Parkes Emerging Homogeneous DNA-based Technologies in the Clinical Laboratory Clin. Chem., June 1, 2001; 47(6): 990 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Van Der Pol, D. V. Ferrero, L. Buck-Barrington, E. Hook III, C. Lenderman, T. Quinn, C. A. Gaydos, J. Lovchik, J. Schachter, J. Moncada, et al. Multicenter Evaluation of the BDProbeTec ET System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Urine Specimens, Female Endocervical Swabs, and Male Urethral Swabs J. Clin. Microbiol., March 1, 2001; 39(3): 1008 - 1016. [Abstract] [Full Text] |
||||
![]() |
J. S. Bergmann, W. E. Keating, and G. L. Woods Clinical Evaluation of the BDProbeTec ET System for Rapid Detection of Mycobacterium tuberculosis J. Clin. Microbiol., February 1, 2000; 38(2): 863 - 865. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |